A NEW study by researchers from Oxford University will investigate whether a drug used to treat inflammatory conditions can be used for coronavirus patients in the community, especially in care homes.
The trial of the anti-tumour necrosis factor (anti-TNF) drug adalimumab will enrol up to 750 patients from community care settings throughout the UK and will be conducted by Oxford Clinical Trials Research Unit.
Anti-TNF drugs have been in widespread use for more than 20 years for a range of inflammatory conditions.
Researchers say recent studies have shown patients with Covid-19 already taking anti-TNF drugs for inflammatory bowel disease and inflammatory arthritis are less likely to be admitted to hospital.
ALSO READ: Randolph Hotel to close for six months and make staff redundant
The same was not observed for patients taking other anti-inflammatory drugs.
Experts say availability of biosimilar versions of biological treatments has been an important step forward in driving down costs, making the anti-TNF treatment affordable and accessible if the trial is successful.
Duncan Richards, professor of clinical therapeutics at Oxford University, said: “The observed potential of anti-TNF drugs has prompted us to conduct a study in patients in community care to see whether treatment with the anti-TNF drug adalimumab reduces the progression to severe or critical disease or death in Covid-19 patients.
“We think anti-TNF drugs could be an important treatment for Covid-19 and are very grateful for the support of the Covid-19 Therapeutics Accelerator, which will allow us to find out.”
The researchers hope to start recruiting patients for the trial in late October.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereLast Updated:
Report this comment Cancel